Bill Ackman’s Pershing Square Holdings posted a slightly negative return in May despite the stock price of Valeant Pharmaceuticals, one of the beleaguered fund's signature positions, remaining relatively stable for most of the period. The decline pushed Pershing Square's 2016 YTD loss to -18.6%.